Pfizer said it will submit an application to the Food and Drug Administration for the RSV vaccine's approval by the end of 2022.
Data shows Pfizer's RSV vaccine given to pregnant mothers as a single dose in the late second or third trimester is effective at protecting newborns, the company said.
RSV is a common respiratory virus that generally causes mild cold-like symptoms, but it can be dangerous for infants younger than 6 months. Pfizer said it will submit an application to the Food and Drug Administration for the vaccine's approval by the end of 2022. The company said it will also submit the results for peer review.
The vaccine was well tolerated with no safety concerns for the mothers or their newborns, according to Pfizer. The mothers were monitored for six months after delivery for any safety concerns, while the babies were followed for at least a year.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
RSV Vaccine Given During Pregnancy Protects Newborns: PfizerNew trial data from drugmaker Pfizer shows promising effectiveness of a vaccine given to mothers during pregnancy that later protects infants in their first months from the most devastating effects of respiratory syncytial virus, or RSV.
Read more »
New RSV vaccine given in pregnancy protects newborns from illness, Pfizer saysThe drugmaker Pfizer announced positive trial results for its RSV vaccine designed to protect newborns.
Read more »
Pfizer develops RSV vaccine for infants given during pregnancyPfizer announced an experimental vaccine that, when administered during pregnancy, would protect infants from severe illness for up to six months of life.
Read more »
RSV Vaccine Given During Pregnancy Protects Newborns: PfizerNew trial data from Pfizer shows promising results of a vaccine given to mothers during pregnancy that later protects infants in their first months from the worst effects RSV. MedTwitter
Read more »
Pfizer claims promising results for maternal RSV vaccine in protecting infantsPfizer's vaccine against respiratory syncytial virus, or RSV, showed promising results protecting newborns when the shot is administered to mothers during the late stages of their pregnancies, according to new clinical trial data from the company.
Read more »